Papillary thyroid microcarcinoma: Is active surveillance always enough?
-
- Rosie Sutherland
- Department of Endocrinology and Diabetes Royal North Shore Hospital Sydney Australia
-
- Venessa Tsang
- Department of Endocrinology and Diabetes Royal North Shore Hospital Sydney Australia
-
- Roderick J. Clifton‐Bligh
- Department of Endocrinology and Diabetes Royal North Shore Hospital Sydney Australia
-
- Matti L. Gild
- Department of Endocrinology and Diabetes Royal North Shore Hospital Sydney Australia
説明
<jats:title>Abstract</jats:title><jats:p>The incidence of papillary thyroid carcinoma (PTC) has increased over recent decades. This apparent epidemic has been attributed to the overdiagnosis of small PTC ≤10 mm in diameter (papillary thyroid microcarcinoma [PTMC]) incidentally detected on imaging for unrelated presentations. Although most PTMCs follow an indolent disease course, there is a small but significant proportion of cases that display more biologically aggressive features such as early metastasis and lymph node involvement. Management of PTMC diagnosed preoperatively should be distinguished from managing those PTMCs incidentally discovered after thyroidectomy. Here, we will focus on the challenge of managing the preoperative patient. Current guidelines recommend against routine biopsy of nodules ≤10 mm, even if they display highly suspicious features on ultrasound; however, it is not known how to identify those PTMCs at higher risk of disease progression. In view of their good prognosis even without surgical resection, active surveillance has emerged as an alternative to operative management for low‐risk PTMC without lymph node involvement or distant metastasis. This review aims to summarise active surveillance data for PTMC and identify clinical features that may differentiate the indolent majority from those PTMCs that exhibit early disease progression and metastasis.</jats:p>
収録刊行物
-
- Clinical Endocrinology
-
Clinical Endocrinology 95 (6), 811-817, 2021-06-28
Wiley
